Chardan Capital restated their buy rating on shares of Minerva Neurosciences (NASDAQ:NERV) in a report published on Monday morning, Zacks.com reports.

Other analysts also recently issued reports about the company. Zacks Investment Research downgraded Minerva Neurosciences from a buy rating to a hold rating in a research report on Tuesday, October 29th. William Blair started coverage on shares of Minerva Neurosciences in a report on Wednesday, September 18th. They issued an outperform rating and a $26.00 price objective on the stock. BidaskClub raised shares of Minerva Neurosciences from a strong sell rating to a sell rating in a research report on Friday, August 23rd. Finally, ValuEngine lowered shares of Minerva Neurosciences from a strong-buy rating to a buy rating in a research note on Monday, September 30th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $17.44.

Minerva Neurosciences stock traded up $0.06 during mid-day trading on Monday, hitting $6.21. The company’s stock had a trading volume of 3,802 shares, compared to its average volume of 379,601. The stock’s fifty day moving average is $5.09 and its two-hundred day moving average is $5.97. The firm has a market capitalization of $240.03 million, a PE ratio of -4.84 and a beta of 1.59. Minerva Neurosciences has a 1 year low of $4.01 and a 1 year high of $8.83.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.01. As a group, analysts predict that Minerva Neurosciences will post -1.5 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of NERV. Metropolitan Life Insurance Co NY purchased a new stake in Minerva Neurosciences in the third quarter valued at approximately $88,000. Millennium Management LLC boosted its position in shares of Minerva Neurosciences by 1,082.0% during the third quarter. Millennium Management LLC now owns 654,577 shares of the biopharmaceutical company’s stock worth $5,072,000 after buying an additional 599,198 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Minerva Neurosciences in the third quarter valued at $1,263,000. State Street Corp grew its stake in shares of Minerva Neurosciences by 11.0% in the third quarter. State Street Corp now owns 614,231 shares of the biopharmaceutical company’s stock valued at $4,760,000 after buying an additional 60,879 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Minerva Neurosciences in the 3rd quarter valued at $35,000. Hedge funds and other institutional investors own 78.94% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Further Reading: Call Option

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.